BACKGROUND: Acute myeloid leukemia (AML) cells harboring mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) produce the oncometabolite 2-hydroxyglutarate (2HG). This study prospectively evaluated the 2HG levels, IDH1/2 mutational status, and outcomes of patients receiving standard chemotherapy for newly diagnosed AML. METHODS: Serial samples of serum, urine, and bone marrow aspirates were collected from patients newly diagnosed with AML, and 2HG levels were measured with mass spectrometry. Patients with baseline serum 2HG levels greater than 1000 ng/mL or marrow pellet 2HG levels greater than 1000 ng/2 × 10 6 cells, which suggested the presence of an IDH1/2 mutation, underwent serial testing. IDH1/2 mutations and estimated variant allele frequencies were identified. AML characteristics were compared with the Wilcoxon test and Fisher's exact test. Disease-free survival and overall survival (OS) were evaluated with log-rank tests and Cox regression. RESULTS: Two hundred and two patients were treated for AML; 51 harbored IDH1/2 mutations. IDH1/2-mutated patients had significantly higher 2HG levels in serum, urine, bone marrow aspirates, and aspirate cell pellets than wild-type patients. A serum 2HG level greater than 534.5 ng/mL was 98.8% specific for the presence of an IDH1/2 mutation. Patients with IDH1/2-mutated AML treated with 7 + 3-based induction had a 2-year event-free survival (EFS) rate of 44% and a 2-year OS rate of 57%. There was no difference in complete remission rates, EFS, or OS between IDH1/2-mutated and wild-type patients. Decreased serum 2HG levels on day 14 as a proportion of the baseline were significantly associated with improvements in EFS (P = .047) and OS (P = .019) in a multivariate analysis. CONCLUSIONS: Among patients with IDH1/2-mutated AML, 2HG levels are highly specific for the mutational status at diagnosis, and they have prognostic relevance in patients receiving standard chemotherapy. Cancer 2019;125:541-549.
INTRODUCTION
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a poor prognosis. Genomic sequencing has identified multiple recurring mutations, [1] [2] [3] [4] including those involving isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2). 2, 5 Isocitrate dehydrogenase (IDH) enzymes catalyze the conversion of isocitrate to α-ketoglutarate, and this leads to the production of reduced nicotinamide adenine dinucleotide phosphate. Recurrent IDH1/2 mutations have been identified in approximately 15% to 25% of patients with AML; to date, the prognostic significance of these mutations among patients treated with conventional chemotherapy is unclear. [6] [7] [8] [9] [10] [11] Altered IDH proteins form heterodimers and catalyze the reduction of α-ketoglutarate to the metabolite 2-hydroxyglutarate (2HG) 12 ; 2HG, normally present at low levels in cells, 13 accumulates in the myeloblasts and serum of affected patients. 14 Excess 2HG appears to promote leukemogenesis through altered epigenetic modification of DNA and histones: it modifies gene transcription and impairs cellular differentiation. 15, 16 Targeted inhibitors of aberrant IDH proteins 17 have been developed and used in clinical trials, 18 and an inhibitor of IDH2 (enasidenib) was recently approved for use in relapsed/refractory AML. As genetic alterations become incorporated into prognostic models and therapeutic Cancer February 15, 2019 decisions, 11 it is increasingly important to characterize the relation between the mutational burden and the functional impact of mutations such as IDH1/2. 19 2HG may provide a marker of disease activity. [20] [21] [22] One retrospective study reported that serum 2HG levels were elevated among IDH1/2-mutant patients, and those with serum 2HG levels greater than 200 ng/mL in remission had shortened overall survival (OS). 23 Serum 2HG levels were suppressed in patients with IDH2-mutant relapsed/refractory AML after treatment with enasidenib. 24 We previously reported preliminary findings of prospective 2HG measurements in an initial cohort of 42 patients with AML, and we found that the serial 2HG levels and IDH1/2 variant allele frequency (VAF) correlated with the response to treatment. 25 In this analysis, we sought to prospectively validate 1) whether 2HG can serve as a biomarker of disease activity and therapeutic response in IDH1/2-mutant AML, 2) how 2HG is related to the type and variant allelic burden of IDH1/2 mutations, and 3) whether these values can contribute to the management and prognostication of patients with IDH1/2-mutant AML treated with standard chemotherapy regimens.
MATERIALS AND METHODS

Patients
We enrolled patients at Massachusetts General Hospital and the Dana-Farber Cancer Institute who were 18 years old or older, had newly diagnosed AML (as defined by World Health Organization criteria), and were candidates for conventional AML treatment between 2011 and 2015. Samples were serially collected through a protocol approved by the Dana-Farber/Harvard Cancer Center institutional review board. Informed consent was obtained in accordance with the principles of the Declaration of Helsinki. 26 Initial therapies for AML included various standard upfront approaches, such as cytarabine and anthracycline (7 + 3)-based induction and hypomethylating agent (HMA) therapy with decitabine or 5-azacitidine.
2HG Samples
Serum, urine, and marrow samples were obtained for 2HG measurement before therapy. Mononuclear cells from blood and marrow aspirates were isolated via density gradient centrifugation with Ficoll-Hypaque (GE Healthcare). 2HG measurement was performed by mass spectrometry with methods previously described and included both R-and S-enantiomers. 12, 19 On the basis of previously published data that predicted for the presence of IDH1/2 mutations, serum and marrow cell pellet 2HG levels at diagnosis were classified as elevated if they were greater than 1000 ng/mL or 1000 ng/2 × 10 6 cells, respectively. 14 Patients with elevated baseline 2HG levels, regardless of their IDH1/2 mutational status, then had serial serum and urine samples collected on days 7, 14, 30, and 60 and at relapse; patients known to have an IDH1/2 mutation at diagnosis had serial samples taken, regardless of their baseline 2HG levels. Bone marrow aspirate samples were also collected at the baseline, on days 14 and 30, at the time of relapse, and when otherwise clinically indicated.
Assays for Mutations in IDH1/2
Testing for IDH1/2 mutations was performed according to local institutional practices; because of the duration of the study, testing methods evolved over time. Patients enrolled at Massachusetts General Hospital had IDH1/2 mutational testing initially via direct sequencing with the Sanger method and subsequently via single-base extension sequencing and next-generation sequencing (NGS) with the SNaPshot assay (Applied Biosystems). 27 Patients enrolled at the Dana-Farber Cancer Institute underwent IDH1/2 testing either via Sanger sequencing or through targeted sequencing via the OncoMAP (2011-2013) or NGS-based OncoPanel platform (2013-2015) 28, 29 or Rapid Heme assays. 30 For patients with NGS-based sequencing, the relative IDH1/2 mutational burden was estimated as the ratio of mutant reads to total reads and was reported as the VAF. Hotspot mutational profiling for NRAS, KRAS, tumor protein 53 (TP53), KIT, fmsrelated tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD), FLT3-tyrosine kinase domain (TKD), nucleophosmin 1 (NPM1), and CCAAT enhancer binding protein α (CEBPA) mutations was performed and documented among patients at either institution.
Statistical Methods
The primary objective of this analysis was to determine whether 2HG levels were associated with therapeutic response and survival after initial chemotherapy. Secondary outcomes included whether the IDH1/2 mutational status and clonal burden, as estimated by the VAF, affected these same measures. The identification of an optimal 2HG threshold associated with the presence of IDH1/2 mutations was performed for all patients who underwent baseline mutational testing via a recursive partitioning algorithm in R version 3.2.1 with the rpart package. Linear relations between 2HG levels at diagnosis and baseline laboratory values were analyzed with software from SAS (Cary, North Carolina) with the glm procedure. Complete remission (CR) or complete remission with incomplete count recovery (CRi) was assessed according to working group criteria. When 2 mutant IDH alleles were detected, the VAF for the larger clone (the higher value) was used in the analysis. Associations between patient and disease characteristics and CR/CRi were assessed with the Wilcoxon rank-sum test, Fisher's exact test, or the Kruskal-Wallis test, as appropriate. OS was defined as the time from diagnosis until death or was censored at the date on which the patient was last known to be alive; event-free survival (EFS) was defined as the time from diagnosis until progression, death, or the date on which the patient was last known to be alive. OS and EFS were estimated with the Kaplan-Meier method, and comparisons were made with a log-rank test or Cox regression. The transplant status was considered in the model as a time-varying covariate.
RESULTS
Patient Population
Between 2011 and 2015, 255 patients with AML were identified ( Table 1) . A total of 15 patients were found to have acute promyelocytic leukemia (APL) and were treated with all-trans retinoic acid-based regimens; no patients with APL had IDH1/2-mutated disease. Thirteen patients received supportive care or low-intensity palliative treatments, and 1 patient transferred to another institution after diagnosis. This resulted in 226 patients receiving conventional upfront therapies for non-APL AML who were then followed prospectively. In this group, 202 patients had IDH1/2 mutational testing results available (Supporting Fig. 1 ); their median age was 65 years at diagnosis. One hundred forty patients (69%) received initial treatment with 7 + 3-based induction chemotherapy. Another 57 patients (28%) were treated with HMA-based therapy. A small number of patients (n = 5 [2%]) were treated with alternative induction regimens (topotecan plus cytarabine [n = 4] or intermediatedose cytarabine [n = 1]).
Patient 2HG Levels
Levels of 2HG at diagnosis were measured in available serum (n = 195), urine (n = 190), bone marrow aspirate (n = 167), and aspirate cell pellet samples (n = 138; Cancer February 15, 2019 Table 1 ). Patients who had baseline serum 2HG levels greater than 1000 ng/mL (n = 37) or marrow cell pellet 2HG levels greater than 1000 ng/2 × 10 6 cells (n = 31) had sequential samples collected during treatment (n = 50). One patient had AML with low baseline 2HG levels and did not undergo serial testing, but mutation testing subsequently showed an IDH2 R132 mutation.
IDH1/2 Mutation Status
A total of 51 of 202 patients tested (25.2%) harbored an IDH1 and/or IDH2 mutation. Twenty-seven patients had IDH2 R140Q mutations, 9 had IDH2 R172 mutations (R172K, n = 8; R172M, n = 1), and 13 had IDH1 R132 mutations (R132C, n = 8; R132H, n = 5). Two additional patients had mutations detected in both IDH1 and IDH2. There was no association between the IDH1/2 mutational status and the patient's age (P = .96) or sex (P = .51). IDH1/2 mutations were enriched among cytogenetically normal patients (P = .001). Among those tested, the frequency of mutations in NRAS, TP53, KIT, FLT3-TKD, or CEBPA were not significantly different between IDH1/2-mutated and wild-type patients, but there was a trend toward higher rates of NPM1 mutations (33% vs 19%; P = .075) and lower rates of KRAS and FLT3-ITD mutations in IDH1/2-mutated AML ( Table 1) . Among 145 patients with a known IDH status receiving induction (7 + 3 or other), a univariate analysis showed no difference between IDH1/2-mutated and wild-type patients in CR/CRi rates (87% vs 77%; P = .24) or OS (P = .309). Patients with IDH1/2 mutations had elevated 2HG levels in comparison with wild-type patients in serum (P < .0001), urine (P < .0001), marrow aspirate (P < .0001), and aspirate cell pellet samples (P < .0001; Fig. 1 and Table 1 ). Levels of marrow 2HG were associated with specific mutant IDH1/2 alleles (P = .038) and white blood cell (WBC) counts at presentation (P = .005). Patients with IDH2 R172K/M mutations had the lowest median bone marrow 2HG level (4270 ng/ mL) and the lowest median WBC count (1560 cells/L) among all IDH1/2-mutant cases. Patients with IDH2 140Q mutations had the highest median marrow 2HG level (39,100 ng/mL) and WBC count (6700 cells/L). IDH1 R132C/H-mutated patients had intermediate values for the median 2HG level (10,030 ng/mL) and WBC count (9700 cells/L). There were no differences in 2HG levels in serum (P = .246), urine (P = .423), or marrow pellet samples (P = .881) by mutation type. Serum 2HG levels, however, did correlate with the peripheral WBC count (R 2 = 0.794; P < .0001) and absolute blast count (R 2 = 0.949; P < .0001). 
Test Characteristics of 2HG
Recursive partitioning was used to characterize the predictive value of 2HG levels for IDH1/2 mutations among a total of 228 patients who underwent IDH1/2 testing, regardless of the subsequent treatment. The optimal test cutoff for 2HG to predict an IDH1/2 mutational presence was above a level of 534.5 ng/mL in the serum (n = 221), 16,650 ng/mL in the urine (n = 213), 2210 ng/ mL in the marrow aspirate (n = 190), and 1146 ng/2 × 10 6 cells in the marrow pellet (n = 159). 2HG values from the serum and marrow pellet had the greatest specificity for the presence of an IDH1/2 mutation (0.988 and 1.00, respectively; Table 2 ). Of those patients with serum or pellet 2HG levels above these cutoffs, 94.5% and 100% were IDH1/2-mutated, respectively. Marrow aspirate 2HG had the greatest sensitivity (0.884) and negative predictive value (0.966) for the presence of an IDH1/2 mutation. Urine 2HG levels were less sensitive than serum 2HG levels (Fig. 2 ). There was a logarithmic relation between the IDH1/2 VAF and baseline 2HG levels, specifically serum and marrow aspirate 2HG levels (Supporting Fig. 2 ).
2HG Measurements and Patient Response to Treatment
Of the 140 patients given 7 + 3-based induction chemotherapy, 38 harbored IDH1/2 mutations (18 with IDH2 R140, 8 with IDH2 R172, 11 with IDH1 R132, and 1 with both IDH1 and IDH2 mutations), and 102 (73%) had the IDH1/2 wild type. HMA-treated patients (n = 57) included 12 with mutated IDH1/2 (9 with IDH2 R140, 2 with IDH1 R132, and 1 with both IDH1 and IDH2 mutations), and 45 were wild-type. The CR/CRi rate was 81% (113 of 139 evaluable patients) among conventional induction patients and 30% (17 of 57) among HMA patients. For the IDH1/2-mutated patients, the CR/ CRi rate was 87% (33 of 38 evaluable patients) among those receiving induction chemotherapy and 42% (5 of 12) among those receiving HMA-based therapies. There was no difference in CR/CRi rates based on the IDH1/2 mutational status for patients receiving induction (P = .31) or HMA-based therapies (P = .32). There was no difference in CR/CRi rates between specific IDH1/2 mutations, although the small number of patients with any given molecular subtype limited the power to detect any difference in remission rates. In addition, among all treated patients, without accounting for the IDH1/2 mutational status, we found no apparent association between attaining remission and baseline 2HG levels in the serum (P = .92), urine (P = .39), marrow aspirate (P = .86), or marrow cell pellet (P = .17).
We characterized the responses and outcomes of the 38 IDH1/2-mutated patients receiving induction according to serum and urine 2HG levels at the baseline and Fig. 3 ). The IDH1/2 mutational burden at diagnosis, as characterized by VAF, did not appear to be associated with achieving CR after standard induction (median VAF, 38% with CR vs 39% with no CR; P = .45) or with changes in 2HG during treatment (Supporting Fig. 4 ). There was no significant association between the IDH1/2 VAF and the presence or absence of concurrent NRAS (P = .297), NPM1 (P = .629), or FLT3-TKD mutations (P = .608); however, patients with concurrent IDH1/2 and FLT3-ITD mutations (n = 4) had a higher baseline IDH1/2 VAF (median, 0.510) than wildtype patients (median, 0.373; P = .0274).
The median EFS and OS of IDH1/2-mutated patients receiving 7 + 3 chemotherapy were 18 and 42.2 months, respectively, with an estimated 2-year EFS rate of 44% and an estimated 2-year OS rate of 57% (Fig. 3 ). There was no significant difference in EFS or OS between IDH1/2-mutated patients and wild-type patients (P for EFS = .40; P for OS = .49). We evaluated serum 2HG on day 14 as a marker of response to chemotherapy to predict EFS and OS among IDH1/2-mutated patients treated with induction chemotherapy. Serum 2HG levels on day 14 as a proportion of the baseline were positively associated with worsened EFS (hazard ratio [HR] for relapse or death, 6.5; P = .047) and OS (HR for death, 24.5; P = .019), such that a patient with a day 14 serum 2HG ratio of 0.7 would have a relative HR for relapse or death of 3.25 and a relative HR for death of 12.25 in comparison with a patient with a ratio of 0.2. Among IDH1/2-mutant patients, transplantation, as a time-varying covariate, showed a trend toward improved EFS (HR, 0.24; P = .062) but was not associated with OS (HR, 0.38; P = .254; Supporting Fig. 5 ). Within the IDH1/2-mutated population, there was no significant association between age, sex, type of IDH mutation, or cytogenetic risk and either EFS or OS (Supporting Table 1 ). Concurrent NPM1 mutations were identified in approximately a third of the IDH1/2-mutated patients; within the IDH1/2-mutated cohort, there was no association between the NPM1 mutation status and 2HG levels, nor was there any impact on EFS (P = .230) or OS (P = .610) when we accounted for changes in 2HG. There was similarly no impact of concurrent FLT3 or NRAS mutations on EFS and OS (data not shown). Although the analysis was limited by the number of mutated patients, the presence of FLT3 and NRAS mutations was not associated with that of IDH1/2 mutational subtypes, such as IDH1 R132, IDH2 R140, and IDH2 R172. In a univariate analysis, IDH1/2-mutated patients with a VAF < 0.25 at diagnosis had improved EFS (P = .020) and a trend toward improved OS (P = .08; Supporting Fig. 6 ). However, when we accounted for the change in 2HG during treatment from the baseline, the VAF at diagnosis no longer affected EFS or OS in a multivariate analysis.
DISCUSSION
Mutations involving IDH1 or IDH2 lead to excess production of the novel oncometabolite 2HG, a potentially unique biomarker that can offer both insight into the pathogenesis of AML and a mechanism for monitoring treatment success. The overall prognostic significance of Cancer February 15, 2019 IDH1/2 mutations among patients with AML remains uncertain on the basis of multiple prior retrospective studies, 4,7-9,31-33 which have offered conflicting results. Earlier data had also suggested that elevated serum levels of 2HG predict for the presence of IDH1/2 mutations in AML. 5, 14 In this study, we sought to establish the sensitivity and specificity of 2HG as a predictor of the IDH mutation status to understand differences in 2HG levels according to the tissue compartment, to characterize the prognostic value of the baseline 2HG levels and IDH mutation status, and to characterize the predictive value of the baseline 2HG levels, IDH mutation status, and dynamic 2HG testing during treatment with standard chemotherapies.
We indeed found that initial 2HG levels had a strong predictive value for the presence of an IDH1/2 mutation. A serum 2HG cutoff of 534.5 ng/mL had a positive predictive value of 95.35% in this series. Although our study used a mass spectrometry technique to assay 2HG, 13, 34 other assays are becoming available, including high-throughput assays that may be able to more rapidly test for 2HG levels. 35 The rapid identification of mutations in patients with high-grade hematologic malignancies and, in particular, AML is increasingly important, even for initial treatment strategies. 36, 37 At the same time, we did identify 2 patients with IDH1/2 wild-type disease with elevations in 2HG: these 2 wild-type patients had elevated baseline 2HG levels (one with a serum level of 1224 and the other with a pellet level of 1124), and both patients had marked leukocytosis at diagnosis (WBC counts, 292,100 and 224,150, respectively). These patients had NGS-based testing, but it is possible that this testing missed a rare subclone, In addition, we identified rare IDH1/2-mutated patients with low 2HG levels; as such, 2HG may not supplant genetic testing but rather may serve as a dynamic marker of disease activity. These data also add to our current understanding of the prognostic implications of specific IDH mutations among patients treated with standard induction chemotherapy, [6] [7] [8] [9] [10] [11] which, though studied to date in multiple retrospective series, remain unclear. Indeed, as targeted agents directed at mutant IDH1 or IDH2 enter the clinic, the clinical outcomes of this subgroup of patients with AML when treated with standard induction chemotherapy remains under debate. In this prospective cohort of patients with AML, those harboring an IDH1/2 mutation had similar CR rates as well as EFS and OS in comparison with patients with IDH1/2 wild-type AML. Interestingly, we identified some variation in outcomes according to the IDH1/2 mutation burden; those patients with a lower baseline VAF had improved EFS in comparison with those with a baseline VAF above 0.25. Further studies of the mutation burden and outcomes in larger cohorts of IDH1/2-mutated patients are needed to verify this association.
With our growing understanding of the prognostic significance of early responses and the clearance of minimal residual disease in other hematologic malignancies, 38 we found that, among those with IDH1/2 mutations receiving induction chemotherapy, a decrease in serum 2HG levels on day 14 with respect to the baseline was associated with significantly improved EFS and OS, even when we accounted for transplantation. This time point is relevant because many patients will have an ablated marrow, and other markers of residual disease may be less sensitive in that state. It is possible that 2HG levels, to some degree, reflect the overall burden of disease or the functional activity of the leukemic cells, but serial measurements appear to provide insight into treatment responses. In a similar fashion, serum 2HG levels appear to track disease responses among patients with relapsed or refractory IDH2-mutated AML treated with enasidenib in early phase trials; however, responses with that targeted agent as monotherapy can vary, and the timing of the 2HG response in that setting is unclear. 24 2HG monitoring may thus offer a strategy for assessing minimal residual disease in AML 39 or a way of selecting appropriate treatment strategies in postremission or posttransplant settings. Comparing 2HG levels with minimal residual disease as measured by flow cytometry or molecular methods may be also be an area for future exploration.
It is worth noting that 2HG levels may prove useful as predictors of CR. However, in this study, the rate of remission among IDH1/2-mutated patients was high, with 33 of 38 patients achieving CR; this limited any power to detect differences in 2HG that may predict the response to conventional induction chemotherapy. That said, patients achieving CR had lower serum 2HG levels on day 14 both as an absolute value (123 vs 250 ng/mL; P = .14) and as a proportion of the baseline (0.14 vs 0.72 of the baseline; P = .07), and this raises the possibility that a minimally invasive test, such as a determination of the serum 2HG level, may be a feasible and relevant strategy for complementing standard bone marrow biopsy for a midtreatment assessment. Larger cohorts of patients with IDH1/2 mutations and an understanding of 2HG and clonal dynamics with combination therapies, such as those incorporating mutant IDH1/2 inhibitors (NCT02677922 and NCT02632708), may provide further insight into novel ways of monitoring responses and targeting interventions in this subgroup of AML. 39 
